David Hutton, Managing Editor, Ophthalmology Times
Bausch + Lomb Corp. announced the US commercial launch of perfluorohexyloctane ophthalmic solution (Miebo) for treatment of the signs and symptoms of dry eye disease (DED).
According to the company, perfluorohexyloctane ophthalmic solution is the first and only prescription eye drop approved for DED that directly targets tear evaporation.
In a news release, Andrew Stewart, president, Global Pharmaceuticals and International Consumer, Bausch + Lomb, pointed out that more and more Americans are suffering from dry eye disease, due in large part to today’s multi-screen lifestyles.
“With MIEBO, eye care professionals now have a prescription eye drop that directly addresses tear evaporation, the leading cause of dry eye disease,” he said in the news release……
Source: Optometry Times